Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SUNRAY-02: Olomorasib + Immunotherapy in KRAS G12C-Mutant NSCLC
NCT06890598Phase 3Recruiting
- Sponsor
- Eli Lilly and Company
- Start
- Mar 2025
- Primary completion
- May 2029
- Modality
- Small Molecules
- Countries
- 29
01
Overview
A Phase 3 trial of olomorasib in non-small cell lung cancer (NSCLC), sponsored by Eli Lilly and Company. Started Mar 2025; status: recruiting.
02
Drugs
olomorasib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT06890598.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06890598.